Marinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of Directors
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, has announced the appointment of Marvin H. Johnson, Jr. to its Board of Directors.
“With over 34 years of diverse commercial operations experience at Merck & Co., we are delighted that Marvin is joining the Marinus Board,” said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus. “His impressive background launching products across multiple therapeutic categories, including neurology and acute care, will be invaluable in supporting the continued commercial success of ZTALMY® and in preparing for a potential hospital launch in status epilepticus.”
During his tenure at Merck & Co., Mr. Johnson held numerous senior leadership roles, primarily within commercial operations, sales, and marketing, across a wide range of therapeutic categories. He led large scale regional, national, and global sales and marketing organizations worth over $3 billion in annual revenue, including in his role as Vice President of the U.S. Human Health East Commercial Operations Group for the Primary Care Sales division and prior to that, Global Brand Leader for Merck’s Migraine franchise where he successfully led product launches in various countries around the world. Most recently, Mr. Johnson was the Chief Learning Officer for Merck’s Global Learning and Development department.
“I am honored to join Marinus’ Board at this pivotal time following the launch of ZTALMY,” said Mr. Johnson. “I look forward to leveraging my expertise in support of the launch planning for the Phase 3 refractory status epilepticus and tuberous sclerosis complex indications and advancing the company’s mission in bringing innovative new treatment options to patients with seizure disorders.”
Mr. Johnson is a member of the Board of Directors for Trevena, Inc., Vice Chair on the Board of Trustees for Tabor Children’s Services, Inc. and serves as a member of the strategic advisory board for GP Strategies Corporation.